Loading company…
MindImmune Therapeutics develops treatments targeting immune cell activity in Alzheimer's disease.
Founded in 2016 and based in Rhode Island, US, MindImmune Therapeutics researches treatments for Alzheimer's disease. Its lead program is an antibody intended to prevent peripheral immune cells from entering the brain and damaging neurons. In November 2025, it raised USD 10.2 million in Series A funding led by Dolby Family Ventures, with Pfizer Venture Investments, Slater Technology Fund, Gates Frontier, The Foundation For A Better World, and other unspecified investors participating. The funding will support preclinical development and preparation for investigational new drug studies.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in